Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca2+ influx and induces streamers

European Journal of Immunology

Volumn 41, Issue 8, 2011, Pages 2436-2446

  Beum, Paul V ^a   Lindorfer, Margaret A ^a   Peek, Elizabeth M ^a   Stukenberg, P Todd ^a   de Weers, Michel ^b   Beurskens, Frank J ^b   Parren, Paul W H I ^b   van de Winkel, Jan G J ^b,c   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Complement; Membrane attack complex; Ofatumumab; Rituximab

Indexed keywords

ALEMTUZUMAB; CALCIUM ION; CD45 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; DARATUMUMAB; DECAY ACCELERATING FACTOR; EDETIC ACID; HM 005; MELITTIN; MEMBRANE LIPID; MONOCLONAL ANTIBODY; OFATUMUMAB; PHOSPHATIDYLSERINE; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CELL COMMUNICATION; CELL MEMBRANE; CELL MOTION; CELL POPULATION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, CD45; ANTIGENS, CD55; B-LYMPHOCYTES; CALCIUM; CELL LINE; CELL LINE, TUMOR; CHELATING AGENTS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; CYTOTOXICITY, IMMUNOLOGIC; EGTAZIC ACID; FLOW CYTOMETRY; HUMANS; MELITTEN; MICROSCOPY, FLUORESCENCE; PHOSPHATIDYLSERINES; SERUM;

EID: 79960744744     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041204     Document Type: Article

References (58)

1. Dunkelberger, J. R. and Song, W. C., Complement and its role in innate and adaptive immune responses. Cell Res. 2010. 20: 34-50.
2. Wagner, E. and Frank, M. M., Therapeutic potential of complement modulation. Nat. Rev. Drug Disc. 2010. 9: 43-56.
3. Ricklin, D., Hajishengallis, G., Yang, K. and Lambris, J. D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010. 11: 785-797.
4. Muller-Eberhard, H. J., The killer molecule of complement. J. Invest. Dermatol. 1985. 85: 47s-52s.
5. Morgan, B. P., Effects of the membrane attack complex of complement on nucleated cells. Curr. Topic. Mircobiol. Immunol. 1992. 178: 115-140.
6. 2+ on the lytic process. J. Immunol. 1987. 138: 1530-1536.
7. Morgan, B. P. and Campbell, A. K., The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem. J. 1985. 231: 205-208.
8. 2+ in complement membrane attack. Cell Calcium 1986. 7: 399-411.
9. Koski, C., Ramm, L., Hammer, C., Mayer, M. and Shin, M., Cytolysis of nucleated cells by complement: Cell death displays multi-hit characteristics. Proc. Natl. Acad. Sci. USA 1983. 80: 3816-3820.
10. Beum, P. V., Lindorfer, M. A., Beurskens, F., Stukenberg, P. T., Lokhorst, H. M., Pawluczkowycz, A. W., Parren, P. W. et al., Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 2008. 181: 822-832.
11. Akiyoshi, K., Itaya, A., Nomura, S. M., Ono, N. and Yoshikawa, K., Induction of neuron-like tubes and liposome networks by cooperative effect of gangliosides and phospholipids. FEBS Lett. 2003. 534: 33-38.
12. Peterlin, P., Arrigler, V., Kogej, K., Svetina, S. and Walde, P., Growth and shape transformation of giant phospholipid vesicles upon interaction with an aqueous oleic acid suspension. Chem. Phys. Lipids 2009. 159: 67-76.
13. Rustom, A., Saffrich, R., Markovic, I., Walther, P. and Gerdes, H.-H., Nanotubular highways for intercellular organelle transport. Science 2004. 303: 1007-1010.
14. Salter, R. D., Tuma-Warrino, R. J., Hu, P. Q. and Watkins, S. C., Rapid and extensive membrane reorganization by dendritic cells following exposure to bacteria revealed by high-resolution imaging. J. Leuk. Biol. 2004. 75: 240-243.
15. Onfelt, B., Nedvetzki, S., Yanagi, K. and Davis, D. M., Membrane nanotubes connect immune cells. J. Immunol. 2004. 173: 1511-1513.
16. Onfelt, B., Nedvetzki, S., Benninger, R. K. P., Purbhoo, M. A., Sowinski, S., Hume, A. N., Seabra, M. C. et al., Structurally distinct membrane nanotubes between human macrophages support long-distance vesicular traffic or surfing of bacteria. J. Immunol. 2006. 177: 8476-8483.
17. Sherer, N. M., Lehmann, M. J., Jiminez-Soto, L. F., Horensavitz, C., Pypaert, M. and Mothes, W., Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 2007. 9: 310-315.
18. Chinnery, H. R., Pearlman, E. and McMenamin, P. G., Membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea. J. Immunol. 2008. 180: 5779-5783.
19. Gurke, S., Barroso, J. F. V. and Gerdes, H. H., The art of cellular communication: tunneling nanotubes bridge the divide. Biochem. Cell Biol. 2008. 129: 539-550.
20. Pontes, B., Viana, N. B., Campanati, L., Farina, M., Neto, V. M. and Nussenzveig, H. M., Structure and elastic properties of tunneling nanotubes. Eur. Biophys. J. 2008. 37: 121-129.
21. Salter, R. D. and Watkins, S. C., Dendritic cell altered states: what role for calcium? Immunol. Rev. 2009. 231: 278-288.
22. Chauveau, A., Aucher, A., Eissmann, P., Vivier, E. and Davis, D. M., Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells. Proc. Natl. Acad. Sci. USA 2010. 107: 5545-5550.
23. Wang, X., Veruki, M. L., Bukoreshtliev, N. V., Hartveit, E. and Gerdes, H. H., Animal cells connected by nanotubes can be electrically coupled through interposed gap-junction channels. Proc. Natl. Acad. Sci. USA 2010. 107: 17194-17199.
24. Whaley, K. and North, J., Haemolytic assays for whole complement activity and individual components, in Dodds, A. W. and Sim, R. B. (Eds.) Complement. A Practical Approach, IRL at Oxford University Press, Oxford 1997, pp. 19-48.
25. Fearon, D. T., Austen, K. F. and Ruddy, S., Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 1973. 138: 1305-1313.
26. Houle, J. J. and Hoffmann, E. M., Evidence for restriction of the ability of complement to lyse homologous erythrocytes. J. Immunol. 1984. 133: 1444-1452.
27. Bara, S. and Lint, T. F., The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J. Immunol. 1987. 138: 1303-1309.
28. Farries, T. C., Steuer, K. L. and Atkinson, J. P., The mechanism of activation of the alternative pathway of complement by cell-bound C4b. Mol. Immunol. 1990. 27: 1155-1161.
29. Gelderman, K. A., Tomlinson, S., Ross, G. D. and Gorter, A., Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004. 25: 158-164.
30. Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I. and Taylor, R. P., Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009. 183: 749-758.
31. Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Bees, S. A., French, R. R., van Meerten, T. et al., The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006. 177: 362-371.
32. Reiter, Y., Ciobotariu, A., Jones, J., Morgan, B. P. and Fishelson, Z., Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J. Immunol. 1995. 155: 2203-2210.
33. Laine, R. O., Morgan, B. P. and Esser, A. F., Comparison between complement and melittin hemolysis: anti-melittin antibodies inhibit complement lysis. Biochemistry 1988. 27: 5308-5314.
34. Salter, R. D. and Watkins, S. C., Dynamic properties of antigen uptake and communication between dendritic cells. Immunol. Res. 2006. 36: 211-220.
35. Beers, S. A., French, R. R., Chan, C. H. T., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S. et al., Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010. 115: 5191-5201.
36. Shirazi, Y., McMorris, F. A. and Shin, M. L., Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyteXC6 glioma cell hybrids. J. Immunol. 1989. 142: 4385-4391.
37. Schreiber, R. D., Pangburn, M. K., Medicus, R. G. and Muller-Eberhard, H. J., Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin. Immunol. Immunopath. 1980. 15: 384-396.
38. Marquart, H. V., Svehag, S. and Leslie, R. G. Q., CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J. Immunol. 1994. 153: 307-315.
39. Kheirallah, S., Caron, P., Gross, E., Quillet-Mary, A., Bertrand-Michel, J., Fournie, J. J., Laurent, G. and Bezombes, C., Rituximab inhibits B-cell receptor signaling. Blood 2010. 115: 985-994.
40. Schlager, S. I., Ohanian, S. H. and Borsos, T., Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C. J. Immunol. 1978. 120: 895-901.
41. Seeger, W., Suttorp, N., Hellwig, A. and Bhakdi, S., Noncytolytic terminal complement complexes may serve as calcium gates to elict leukotriene B4 generation in human polymorphonuclear leukocytes. J. Immunol. 1986. 137: 1286-1293.
42. Ansa-Addo, E. A., Lange, S., Stratton, D., Antwi-Baffour, S., Cestari, I., Ramirex, M. I., McCrossan, M. V. and Inal, J. M., Human plasma membrane-derived vesicles halt proliferation and induce differentiation of THP-1 acute monocytic leukemia cells. J. Immunol. 2010. 185: 5236-5246.
43. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G. et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 2000. 18: 3135-3143.
44. Cheson, B. D. and Leonard, J. P., Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. New Engl. J. Med. 2008. 359: 613-626.
45. Martin, A., Conde, E., Arnan, M., Canales, M. A., Deben, G., Sancho, J. M., Andreu, R. et al., R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008. 93: 1829-1836.
46. Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M. et al., Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010. 142: 699-713.
47. Black, S. M., Schott, M. E., Batdorf, B. H., Benson, B. A., Rutherford, M. S., Levay-Young, B. K. and Dalmasso, A. P., IL-4 induces protection of vascular endothelial cells against killing by complment and melittin through lipid biosynthesis. Eur. J. Immunol. 2010. 40: 803-812.
48. Wilschut, J., Duzgunes, N., Fraley, R. and Papahadjopoulos, D., Studies on the mechanism of membrane fusion: kinetics of calcium ion induced fusion of phosphatidylserine vesicles followed by a new assay for mixing of aqueous vesicle contents. Biochemistry 1980. 19: 6011-6021.
49. Kunzelmann-Marche, C., Freyssinet, J. M. and Martinez, M. C., Regulation of phosphatidylserine transbilayer redistribution by store-operated Ca2+ entry. J. Biol. Chem. 2001. 276: 5134-5139.
50. King, L. B. and Freedman, B. D., B-lymphocyte calcium influx. Immunol. Rev. 2009. 231: 265-277.
51. Papahadjopoulos, D., Vail, W. J., Jacobson, K. and Poste, G., Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta 1975. 394: 483-491.
52. de Weers, M., Tai, Y. T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A. et al., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 2011. 186: 1840-1848.
53. Gerritsen, A. F., Bosch, M., de Weers, M., van de Winkel, J. G. J. and Parren, P. W. H. I., High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. J. Immunol. Methods 2010. 352: 140-146.
54. Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L. and Taylor, R. P., An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood 2003. 101: 1071-1079.
55. Harris, C. L., Lublin, D. M. and Morgan, B. P., Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J. Immunol. Methods 2002. 268: 245-258.
56. Beum, P. V., Kennedy, A. D., Williams, M. E., Lindorfer, M. A. and Taylor, R. P., The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 2006. 176: 2600-2609.
57. DiLillo, D. J., Pawluczkowycz, A. W., Peng, W., Kennedy, A. D., Beum, P. V., Lindorfer, M. A. and Taylor, R. P., Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol. Immunol. 2006. 43: 1010-1019.
58. Williams, M. E., Densmore, J. J., Pawluczkowycz, A. W., Beum, P. V., Kennedy, A. D., Lindorfer, M. A. et al., Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 2006. 177: 7435-7443.